FDA Advisory Panel to Review Seven Peptides in July 2026: What Prescribers Need to Know

Update — May 26, 2026: The official PCAC agenda has been published. The July 23–24 compound list differs from initial reporting. Corrected details are below. AOD-9604, Thymosin Alpha-1, CJC-1295, Ipamorelin, and Selank are in a separate PCAC cohort scheduled before February 2027. See our updated analysis for the full picture.

What the FDA Announced

In April 2026, the FDA issued a federal notice scheduling a July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting to evaluate seven peptides for possible inclusion on the 503A bulk substances list:

Day 1 — July 23:

• BPC-157 (free base and acetate) — ulcerative colitis indication
• KPV — wound healing
• TB-500 (Thymosin Beta-4 fragment) — wound healing
• MOTS-C — metabolic conditions

Day 2 — July 24:

• Emideltide (DSIP) — Delta Sleep-Inducing Peptide
• Semax — neuroprotective ACTH analog
• Epitalon — longevity/pineal peptide

A second PCAC cohort — CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank — was referred in September 2024 and is scheduled for a separate review before February 2027.

This is not routine. Advisory panel reviews at this scale — seven compounds simultaneously — signal that FDA is moving toward a formal reclassification decision rather than case-by-case enforcement.

Why This Review Matters

The practical regulatory status of most peptides has operated in a gap: not FDA-approved, not on the 503A bulk substances list, but not aggressively enforced either. That gap is closing.

The GLP-1 compounding crackdown (2024) demonstrated FDA’s willingness to use the shortage list removal mechanism to end widespread compounding practically overnight. An advisory panel review creates the procedural basis for more formal action.

What’s different this time: Thymosin Alpha-1 and Ipamorelin are on this list. TA1 has regulatory approval in 35+ countries and a substantial human evidence base. Ipamorelin is among the most widely prescribed peptides in US functional medicine. Including these compounds suggests the panel scope extends beyond just research chemicals.

The Seven Compounds: Where Each Stands

BPC-157 — Strong preclinical evidence, no FDA approval, never on 503A list. FDA has issued warning letters to vendors. The Phase II IBD data from Croatia remains unpublished. Most at-risk for adverse finding.

TB-500 — Often confused with Thymosin Beta-4 (TB4). Neither is on the 503A list. Limited human data. Research-only legal status. Moderate preclinical evidence for tissue repair.

AOD-9604 — hGH fragment (176-191). Originally developed by Metabolic Pharmaceuticals for obesity; failed Phase III. No longer has any active IND. Limited ongoing research. High risk for unfavorable classification.

Thymosin Alpha-1 — Approved in 35+ countries (SciClone’s Zadaxin) for HBV, HCV, and cancer supportive care. The strongest evidence base of the seven. The FDA’s decision here would be a significant signal — approval-pathway recommendation vs. restriction.

CJC-1295 — GHRH analog with DAC modification. Not on 503A list. Widely compounded. Phase I/II data limited. The panel will likely focus on the quality of existing human pharmacokinetic data.

Ipamorelin — Cleanest tolerability profile of the GHRPs. Not on 503A list. Widely prescribed in anti-aging and hormone optimization practices. Ferring Pharmaceuticals holds intellectual property; no active NDA.

Epithalon — Research comes almost entirely from Khavinson’s group in Russia. No Western Phase II trials. Weakest evidence base of the seven. High risk for unfavorable classification.

Possible Outcomes

The panel’s review can lead to several outcomes:

1. Addition to 503A bulk substances list — permits compounding; the best-case scenario for prescribers
2. Nomination for further study — maintains status quo temporarily, creates timeline for future decision
3. Adverse finding — basis for enforcement action against compounding and distribution
4. No recommendation — effectively punts the decision; regulatory gray area persists

History suggests outcomes vary by compound: TA1 has the profile for a 503A listing recommendation. BPC-157 and AOD-9604 are at higher risk for adverse findings. Ipamorelin and CJC-1295 are in the middle — strong clinical use, weak formal evidence base.

What Practitioners Should Do Now

Document your rationale. If you’re currently prescribing any of these compounds, your clinical documentation needs to clearly articulate the evidence basis and patient indication. Adverse findings don’t retroactively create liability for prior prescribing, but they do change the forward risk calculus.

Watch the 503A nominations. If a professional organization nominates any of these for the bulk substances list before the panel convenes, that affects the proceedings.

The July timeline is tight. If you have comments on specific compounds, the FDA public comment window associated with advisory panel notices is typically 60–90 days. Watch for the formal Federal Register notice.

Bottom Line

This is the most significant regulatory event for the peptide compounding market since the GLP-1 shortage resolution in 2024. The panel’s findings will likely define the practical prescribing landscape for these seven compounds for years. The outcomes are genuinely uncertain — Thymosin Alpha-1 could come out better than it went in; BPC-157 and AOD-9604 face real downside risk.

We’ll cover the panel findings in real time. Subscribe to the Ercle newsletter for updates as they happen.